619.541.6609
We are available 24/7
Breast mesh lawsuits did not appear out of nowhere.
They follow years of litigation involving other devices used in women's healthcare, including transvaginal mesh, breast implants linked to BIA-ALCL, Essure birth control devices, Paragard IUDs, power morcellators, and ovarian cancer claims tied to talcum powder. Each of these cases involves different conditions and different legal theories, but many share the same underlying complaints, and breast mesh now sits within that same pattern.
Lawsuits involving women's health devices tend to raise a similar set of claims regardless of the specific product, including that long-term safety testing was inadequate before the device reached widespread use, that patients and physicians were not warned of known risks, that marketing moved faster than the clinical evidence supporting it, and that manufacturers or regulators were slow to recognize adverse events once they started appearing. Each case still has to be evaluated on its own facts, and the existence of litigation does not by itself establish that a company is liable.
Earlier mesh litigation centered largely on transvaginal mesh used for pelvic organ prolapse and incontinence. Breast mesh investigations focus on a different application entirely: surgical mesh used during breast reconstruction, breast augmentation, breast lift procedures, and the so-called internal bra technique. The FDA has been direct about the gap here, stating that no surgical mesh product has been cleared or approved for breast surgery and that safety and effectiveness for breast reconstruction and augmentation have not been established. Despite that, products including certain BD GalaFLEX and Phasix lines saw growing off-label use in these procedures, which led the FDA to update its labeling requirements in 2023.
A pattern across this category of litigation is that devices reach broad clinical use before enough long-term data exists to answer basic questions, such as how durable the device is over time, how it performs outside controlled studies, how often complications occur years later, what the impact is on quality of life, and how often patients end up needing revision surgery. The FDA's 2023 statement on BD mesh fits this pattern directly, since the agency said it has not determined the safety and effectiveness of these products for breast surgery and pointed to the need for more evidence before that question can be answered.
One reason these lawsuits draw attention beyond the individual plaintiffs involved is that the discovery process often surfaces internal company documents, clinical study data, adverse event reports, marketing materials, and communications between manufacturers and regulators. This information does not surface through any other channel in most cases. Litigation has repeatedly contributed to public awareness of device-related risks and has, in a number of past cases, led manufacturers or regulators to revise warnings or labeling after the fact.
Regulatory communications do not just sit in a file. For breast mesh, the FDA's 2023 actions led to updated warnings and precautions on several BD products, a clear statement that no surgical mesh is cleared for breast surgery, and a reminder to providers to review the new labeling before continuing to use these products. The FDA stopped short of a recall and did not prohibit off-label use, but the communication has already shaped conversations between surgeons and patients about consent and risk disclosure.
A theme that runs through nearly every women's health device case is whether patients had what they needed to make an informed choice, including whether a device was actually FDA approved or cleared for the specific use proposed, whether the procedure involved an off-label application, what the known risks and complications were, what alternatives existed, and how strong the clinical evidence behind the device actually was. Many lawsuits allege that patients were not given this information before treatment, and those allegations remain subject to proof.
Breast mesh litigation is still considerably earlier in its development than transvaginal mesh litigation, which produced large multidistrict proceedings and numerous settlements over the years. As of 2026, no nationwide MDL has been established specifically for breast mesh cases, no global settlement program has been announced, and individual lawsuits and investigations are still developing. That stage of litigation does not mean claims lack merit. It means the legal record is still being built, often through the same discovery process that has shaped outcomes in earlier women's health device cases.
If you had breast mesh used in a reconstruction, augmentation, or lift procedure and experienced infection, chronic pain, implant complications, or needed revision surgery, your situation may fit within this developing litigation. Atraxia Law can review your medical history, identify the product involved, and help you understand your options. Contact Atraxia Law to find out where your case stands, at no cost and with no obligation.